Adaptation or selection - Mechanisms of castration-resistant prostate cancer

Nature Reviews Urology

Volumn 10, Issue 2, 2013, Pages 90-98

  Zong, Yang ^a   Goldstein, Andrew S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; DEGARELIX; ENZALUTAMIDE; GOSERELIN; HISTRELIN; KETOCONAZOLE; LEUPRORELIN; ORTERONEL;

ADAPTATION; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER CELL; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; MOLECULAR MECHANICS; ORCHIECTOMY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADAPTATION, PHYSIOLOGICAL; ANDROGEN ANTAGONISTS; ANIMALS; CASTRATION; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84873738494     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2012.237     Document Type: Review

References (111)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
2. Huggins, C. & Hodges, C. V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293-297 (1941).
3. Huggins, C., Stevens, R. E. & Hodges, C. V. Studies on prostate cancer II: the effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209-223 (1941).
4. Gomella, L. G. Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev. Urol. 11, 52-60 (2009).
5. Hellerstedt, B. A. & Pienta, K. J. The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 52, 154-179 (2002).
6. Isaacs, J. T. & Coffey, D. S. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res. 41, 5070-5075 (1981).
7. Glickman, M. S. & Sawyers, C. L. Converting cancer therapies into cures: lessons from infectious diseases. Cell 148, 1089-1098 (2012).
8. Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45 (2001).
9. Scher, H. I. & Sawyers, C. L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23, 8253-8261 (2005).
10. Yu, E. Y. et al. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J. Clin. Oncol. 28, 2668-2673 (2010).
11. Ryan, C. J. et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology 68, 834-839 (2006).
12. Shah, R. B. et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 64, 9209-9216 (2004).
13. Crnalic, S. et al. Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients. Endocr. Relat. Cancer 17, 885-895 (2010).
14. Holzbeierlein, J. et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164, 217-227 (2004).
15. Mousses, S. et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 20, 6718-6723 (2001).
16. Zegarra-Moro, O. L., Schmidt, L. J., Huang, H. & Tindall, D. J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 62, 1008-1013 (2002).
17. Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39 (2004).
18. Cheng, H., Snoek, R., Ghaidi, F., Cox, M. E. & Rennie, P. S. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res. 66, 10613-10620 (2006).
19. Snoek, R. et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin. Cancer Res. 15, 39-47 (2009).
20. Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790 (2009).
21. Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375, 1437-1446 (2010).
22. Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563-4571 (2008).
23. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
24. Heemers, H. V. & Tindall, D. J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28, 778-808 (2007).
25. Ryan, C. J. & Tindall, D. J. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J. Clin. Oncol. 29, 3651-3658 (2011).
26. Labrie, F. Endocrine therapy for prostate cancer. Endocrinol. Metab. Clin. North Am. 20, 845-872 (1991).
27. Mizokami, A. et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res. 64, 765-771 (2004).
28. Mostaghel, E. A. et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67, 5033-5041 (2007).
29. Mohler, J. L. et al. The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 10, 440-448 (2004).
30. Stanbrough, M. et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66, 2815-2825 (2006).
31. Chang, K.-H. et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 108, 13728-13733 (2011).
32. Mohler, J. L. et al. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res. 71, 1486-1496 (2011).
33. Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447-4454 (2008).
34. Cai, C. et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 71, 6503-6513 (2011).
35. Locke, J. A. et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68, 6407-6415 (2008).
36. Lubik, A. A. et al. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res. 71, 5754-5764 (2011).
37. Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173, 534-540 (1990).
38. Buchanan, G. et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin. Cancer Res. 7, 1273-1281 (2001).
39. Fleischmann, A. et al. Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. Prostate 71, 453-460 (2011).
40. Donovan, M. J. et al. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int. 105, 462-467 (2010).
41. Waltering, K. K., Urbanucci, A. & Visakorpi, T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol. Cell Endocrinol. 360, 38-43 (2012).
42. Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9, 401-406 (1995).
43. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
44. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
45. Friedlander, T. W. et al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res. 72, 616-625 (2012).
46. Ruiz, C. et al. Advancing a clinically relevant perspective of the clonal nature of cancer. Proc. Natl Acad. Sci. USA 108, 12054-12059 (2011).
47. Bubendorf, L. et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 59, 803-806 (1999).
48. Sharma, A. et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J. Clin. Invest. 120, 4478-4492 (2010).
49. Cai, C. et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20, 457-471 (2011).
50. Tepper, C. G. et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res. 62, 6606-6614 (2002).
51. Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L. & Tindall, D. J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68, 5469-5477 (2008).
52. Guo, Z. et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69, 2305-2313 (2009).
53. Hu, R. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16-22 (2009).
54. Sun, S. et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 120, 2715-2730 (2010).
55. Watson, P. A. et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl Acad. Sci. USA 107, 16759-16765 (2010).
56. Hu, R. et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 72, 3457-3462 (2012).
57. Hobisch, A. et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 58, 4640-4645 (1998).
58. Ueda, T., Mawji, N. R., Bruchovsky, N. & Sadar, M. D. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem. 277, 38087-38094 (2002).
59. Culig, Z. et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54, 5474-5478 (1994).
60. Lee, L. F., Guan, J., Qiu, Y. & Kung, H. J. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol. Cell Biol. 21, 8385-8397 (2001).
61. Craft, N., Shostak, Y., Carey, M. & Sawyers, C. L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5, 280-285 (1999).
62. Guo, Z. et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10, 309-319 (2006).
63. Dai, B. et al. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res. 70, 5587-5596 (2010).
64. Xu, K. et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 15, 270-282 (2009).
65. van Bokhoven, A. et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 57, 205-225 (2003).
66. McDonnell, T. J. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52, 6940-6944 (1992).
67. Liu, A. Y., Corey, E., Bladou, F., Lange, P. H. & Vessella, R. L. Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int. J. Cancer 65, 85-89 (1996).
68. Tanaka, H. et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat. Med. 16, 1414-1420 (2010).
69. Jennbacken, K. et al. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr. Relat. Cancer 17, 469-479 (2010).
70. Sun, Y. et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res. 72, 527-536 (2012).
71. Mulholland, D. J., Jiao, J. & Wu, H. Hormone refractory prostate cancer: lessons learned from the PTEN prostate cancer model. Adv. Exp. Med. Biol. 617, 87-95 (2008).
72. Gao, H. et al. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc. Natl Acad. Sci. USA 103, 14477-14482 (2006).
73. Jiao, J. et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res. 67, 6083-6091 (2007).
74. Carver, B. S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586 (2011).
75. Mulholland, D. J. et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19, 792-804 (2011).
76. Memarzadeh, S. et al. Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. Proc. Natl Acad. Sci. USA 108, 7962-7967 (2011).
77. Ammirante, M., Luo, J.-L., Grivennikov, S., Nedospasov, S. & Karin, M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464, 302-305 (2010).
78. Gingrich, J. R. et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 57, 4687-4691 (1997).
79. Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M. & Abate-Shen, C. Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res. 66, 7929-7933 (2006).
80. Craft, N. et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 59, 5030-5036 (1999).
81. Germann, M. et al. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells 30, 1076-1086 (2012).
82. Marcelli, M. et al. Androgen receptor mutations in prostate cancer. Cancer Res. 60, 944-949 (2000).
83. Thompson, J. et al. Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Lab. Invest. 83, 1709-1713 (2003).
84. Goldstein, A. S., Stoyanova, T. & Witte, O. N. Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol. Oncol. 4, 385-396 (2010).
85. Sar, M., Lubahn, D. B., French, F. S. & Wilson, E. M. Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology 127, 3180-3186 (1990).
86. Bonkhoff, H. & Remberger, K. Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch. A Pathol. Anat. Histopathol. 422, 35-38 (1993).
87. Lawson, D. A. et al. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc. Natl Acad. Sci. USA 107 2610-2615 (2010).
88. Kyprianou, N. & Isaacs, J. T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122, 552-562 (1988).
89. Bonkhoff, H. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate Suppl. 8, 18-22 (1998).
90. Huang, J. et al. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 66, 1399-1406 (2006).
91. van Leenders, G. J., Aalders, T. W., Hulsbergen-van de Kaa, C. A., Ruiter, D. J. & Schalken, J. A. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J. Pathol. 195, 563-570 (2001).
92. Hirano, D., Okada, Y., Minei, S., Takimoto, Y. & Nemoto, N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur. Urol. 45 586-592 (2004).
93. Wang, X. et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461, 495-500 (2009).
94. Ma, X. et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res. 65, 5730-5739 (2005).
95. Choi, N., Zhang, B., Zhang, L., Ittmann, M. & Xin, L. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 21, 253-265 (2012).
96. Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P. & Witte, O. N. Identification of a cell of origin for human prostate cancer. Science 329, 568-571 (2010).
97. Mulholland, D. J. et al. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res. 69, 8555-8562 (2009).
98. Chen, H. et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the p53 pathway. Endocr. Relat. Cancer 19 321-331 (2012).
99. Sutherland, K. D. et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 19, 754-764 (2011).
100. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
101. Magee, J. A., Piskounova, E. & Morrison, S. J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296 (2012).
102. Clevers, H. The cancer stem cell: premises, promises and challenges. Nat. Med. 17 313-319 (2011).
103. Zhou, B. B. et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8 806-823 (2009).
104. Wicha, M. S., Liu, S. & Dontu, G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 66, 1883-1896 (2006).
105. Patrawala, L. et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 65, 6207-6219 (2005).
106. van den Hoogen, C. et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res. 70 5163-5173 (2010).
107. Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J. & Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946-10951 (2005).
108. Guzmán-Ramirez, N. et al. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 69, 1683-1693 (2009).
109. Gu, G., Yuan, J., Wills, M. & Kasper, S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 67, 4807-4815 (2007).
110. Patrawala, L. et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25, 1696-1708 (2006).
111. Mukherji, D., Eichholz, A. & De Bono, J. S. Management of metastatic castration-resistant prostate cancer: recent advances. Drugs 72, 1011-1028 (2012).